Progenics Pharmaceuticals (NASDAQ:PGNX) reported Q4 2017 earnings this Morning, coming in at ($0.04) per share, beating Wall Street’s estimates of ($0.23) per Share. Revenue for the quarter came in at $3.90 million beating analyst estimates of $3.18 million Recent Insider Trading for Progenics Pharmaceuticals (NASDAQ:PGNX)
- On 2/15/2017 Healthcare Master Fun Broadfin, Major Shareholder, sold 602,600 with an average share price of $9.66 per share and the total transaction amounting to $5,821,116.00.
- On 2/9/2017 Healthcare Master Fun Broadfin, Major Shareholder, sold 351,300 with an average share price of $9.71 per share and the total transaction amounting to $3,411,123.00.
- On 6/11/2015 Robert J Israel, EVP, sold 2,000 with an average share price of $6.83 per share and the total transaction amounting to $13,660.00.
- On 3/13/2015 Robert J Israel, EVP, sold 3,000 with an average share price of $7.00 per share and the total transaction amounting to $21,000.00.
- On 3/11/2015 Robert J Israel, EVP, sold 2,000 with an average share price of $6.83 per share and the total transaction amounting to $13,660.00.
- On 3/3/2015 Robert J Israel, EVP, sold 5,000 with an average share price of $6.49 per share and the total transaction amounting to $32,450.00.
Recent Trading for Progenics Pharmaceuticals (NASDAQ:PGNX) Shares of Progenics Pharmaceuticals closed the previous trading session at 7.47 up +0.25 3.46% with 7.449999809265137 shares trading hands.